EP1567178A1 - Modulatoren von rezeptoren für nebenschilddrüsenhormon- und nebenschildsrüsenhormonbezogene proteine - Google Patents

Modulatoren von rezeptoren für nebenschilddrüsenhormon- und nebenschildsrüsenhormonbezogene proteine

Info

Publication number
EP1567178A1
EP1567178A1 EP02793926A EP02793926A EP1567178A1 EP 1567178 A1 EP1567178 A1 EP 1567178A1 EP 02793926 A EP02793926 A EP 02793926A EP 02793926 A EP02793926 A EP 02793926A EP 1567178 A1 EP1567178 A1 EP 1567178A1
Authority
EP
European Patent Office
Prior art keywords
residue
nonfunctional
pth
amino acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02793926A
Other languages
English (en)
French (fr)
Other versions
EP1567178A4 (de
Inventor
Paul Kostenuik
Colin V. Gegg
Mark Anthony Jarosinski
Olaf Boris Kinstler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP1567178A1 publication Critical patent/EP1567178A1/de
Publication of EP1567178A4 publication Critical patent/EP1567178A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention relates to parathyroid hormone PTH), parathyroid hormone-related protein (PTHrP) and modulators of PTH and PTHrP receptors.
  • This invention also relates to proteins modified for extended half-life and, in particular, to proteins modified with polyethylene glycol.
  • PTH and PTHrP play important physiological roles in calcium homeostasis and in development, respectively.
  • Calcium concentration in the blood is tightly regulated, due to the essential role of calcium in cell metabolism.
  • PTH is an endocrine hormone which is secreted from the parathyroid gland in response to decreased serum calcium levels. PTH acts directly to increase bone resorption and to stimulate renal calcium reabsorption, thus increasing or preserving circulating calcium stores.
  • PTH also indirectly increases calcium absorption in the gut by stimulating the renal hydroxylation of vitamin D.
  • Both primary and secondary hyperparathyroidism are conditions that are associated with excessive levels of circulating parathyroid hormone. Through the aforementioned pathways, excess PTH levels can cause hypercalcemia and osteopenia. Bone resorption inhibitors such as bisphosphonates and OPG can effectively protect bone and can inhibit the skeleton's contribution to hypercalcemia. However, the calcemic effects of hyperparathyroidism on the kidney and gut are not addressed by currently available therapy.
  • PTHrP is produced by many cell types, and plays an important role in regulating skeletal development. Postnatally, the roles for PTHrP are less clearly defined. Circulating levels of PTHrP are essentially non- detectable in normal healthy adults. However, many tumors of diverse embryological origins produce and secrete PTHrP in quantities sufficient to cause hypercalcemia. In fact, humoral hypercalcemia of malignancy (HHM) is the most common paraneoplastic syndrome, which accounts for significant patient morbidity and mortality.
  • HHM humoral hypercalcemia of malignancy
  • HHM is treated with saline hydration followed by bone resorption inhibitors such as bisphosphonates.
  • This treatment regimen typically takes 3-4 days to achieve significant reductions in serum calcium, and the effects are relatively short-lived (less than one month).
  • the effects of current treatment options are even less impressive.
  • Repeated administration of conventional therapies are usually progressively less effective.
  • PTHrP Bone resorption inhibitors such as bisphosphonates only inhibit bone resorption, while PTHrP also has significant calcemic effects on the kidney and the gut. Total neutralization of PTHrP would be the ideal adjuvant therapeutic approach to treatment of HHM.
  • PTH and PTHrP interact with PTH-1 receptor, which accounts for most of their known effects. Mannstadt et al. (1999), Am. T. Ph siol. 277. 5Pt 2. F665-75 (1999). Only PTH interacts with the newly discovered PTH-2 receptor.
  • PTHrP can be changed to a PTH-2 receptor agonist, however, by changing two residues to the residues at those positions in PTH.
  • Gardella et al- (1996), T. Biol. Chem. 271 (33): 19888-93.
  • N-terminal fragment of PTH has been used as a therapeutic agent.
  • Intermittently administered native PTH-(l-84) exhibits osteogenic properties, and it has been recognized for decades that these properties can be fully realized with the C-terminally truncated fragment PTH-(l-34).
  • Both peptides bind and activate the PTH-1 receptor with similar affinities, causing the activation of adenylate cyclase (AC) as well as phospholipase C (PLC).
  • AC activation through PTH-1 receptor generates cAMP
  • PLC activation through PTH-1 receptor generates PKC and intracellular calcium transients.
  • PTH-(l-34) can maximally activate both the AC and the PLC pathways.
  • hPTH-(l-31) has a slightly reduced (1-6 fold) affinity for PTH-1 receptor compared to hPTH-(l-34), while hPTH-(l-30) has a significantly reduced (10-100 fold) affinity Takasu (1998). Perhaps due to this decreased PTH-1 receptor affinity, PTH-(l-30) is a weak and incomplete agonist for PLC activation via the rat PTH-1 receptor. Compared to PTH-(l-34), PTH-(1-31) has similar or slightly reduced anabolic potential (Rixon et al. (1994); Whitfield et al.
  • PTH-(1-31) also has slightly reduced PLC activation. Takasu (1998). In healthy humans, infusion of PTH-(1-31) and PTH-(l-34) had similar stimulatory effects on plasma and urinary cAMP concentration, but unlike PTH-(l-34), PTH-(1-31) failed to elevate serum calcium, plasma l,25(OH)2D3, or urinary N-TX levels. Fraher et al. (1999), T. Clin. Endocrin. Met. 84: 2739-43.
  • PTH-(1-31) has diminished capacity to induce bone resorption and to stimulation vitamin D synthesis, which is a favorable profile for bone anabolic agents.
  • PTH-(l-30) was initially shown to lack anabolic properties Whitfield et al- (1996), Calcified Tissue International 53: 81-7. More recently, however, it has been demonstrated that PTH-(l-30) is anabolic when administered at very high doses (400-2,000 ⁇ g/kg, vs. 80 ⁇ g/kg for PTH-(l-34)).
  • the lower potency of PTH-(l-30) could be predicted by its lower binding affinity for PTH-1 receptor, its diminished cAMP activation, and/or to its greatly diminished PKC activation. Takasu (1998). It remains to be determined whether PTH-(l-30) has a similar or even more desirable reduction in apparent bone resorption activity.
  • PTH-(l-28) is the smallest reported fragment to fully activate cAMP. Neugebauer et al. (1995), Biochem. 34: 8835-42. However, hPTH- (1-28) was initially reported to have no osteogenic effects in OVX rats. Miller et al. (1997), T. Bone Min. Res. 12: S320 (Abstract). Recently, a very high dose of PTH-(l-28) (1,000 ⁇ g/kg/ day) was shown to be anabolic in OVX rats, whereas 200 ⁇ g/kg/ day was ineffective. Whitfield et al. (2000), T. Bone Min. Res. 15: 964-70. The diminished or absent anabolic effects of some truncated PTH fragments has been attributed to rapid clearance in vivo. Rixon et al. (1994).
  • Recombinant and modified proteins are an emerging class of therapeutic agents.
  • Useful modifications of protein therapeutic agents include combination with the "Fc" domain of an antibody and linkage to polymers such as polyethylene glycol (PEG) and dextran. Such modifications are discussed in detail in a patent application entitled,
  • Such peptides may mimic the bioactivity of the large protein ligand ("peptide agonists") or, through competitive binding, inhibit the bioactivity of the large protein ligand ("peptide antagonists").
  • Phage display peptide libraries have emerged as a powerful method in identifying such peptide agonists and antagonists. See, for example, Scott et al- (1990), Science 249: 386; Devlin et al- (1990), Science 249: 404; U.S. Pat. No. 5,223,409, issued June 29, 1993; U.S. Pat. No. 5,733,731, issued March 31, 1998; U.S. Pat. No. 5,498,530, issued March 12, 1996; U.S. Pat. No.
  • the best binding peptides may be sequenced to identify key residues within one or more structurally related families of peptides. See, e.g., Cwirla et al. (1997), Science 276: 1696-9, in which two distinct families were identified.
  • the peptide sequences may also suggest which residues may be safely replaced by alanine scanning or by mutagenesis at the DNA level. Mutagenesis libraries may be created and screened to further optimize the sequence of the best binders. Lowman (1997), Ann. Rev. Biophys. Biomol. Struct. 26: 401-24.
  • Structural analysis of protein-protein interaction may also be used to suggest peptides that mimic the binding activity of large protein ligands.
  • the crystal structure may suggest the identity and relative orientation of critical residues of the large protein ligand, from which a peptide may be designed. See, e.g., Takasaki et al. (1997), Nature Biotech. 15: 1266-70.
  • These analytical methods may also be used to investigate the interaction between a receptor protein and peptides selected by phage display, which may suggest further modification of the peptides to increase binding affinity.
  • E. coli display Another E. coli-based method allows display on the cell's outer membrane by fusion with a peptidoglycan-associated lipoprotein (PAL).
  • PAL peptidoglycan-associated lipoprotein
  • E. coli display In another method, translation of random RNA is halted prior to ribosome release, resulting in a library of polypeptides with their associated RNA still attached. Hereinafter, this and related methods are collectively referred to as "ribosome display.”
  • Other methods employ peptides linked to RNA; for example, PROfusion technology, Phylos, Inc.
  • RNA-peptide screening Chemically derived peptide libraries have been developed in which peptides are immobilized on stable, non-biological materials, such as polyethylene rods or solvent-permeable resins. Another chemically derived peptide library uses photolithography to scan peptides immobilized on glass slides. Hereinafter, these and related methods are collectively referred to as “chemical-peptide screening.” Chemical-peptide screening may be advantageous in that it allows use of D-amino acids and other unnatural analogues, as well as non-peptide elements.
  • modulators of PTH and PTHrP comprise: a) a PTH/PTHrP modulating domain, preferably the amino acid sequence of PTH/PTHrP modulating domains of PTH and /or PTHrP, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above; and b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the carboxyl terminus of the PTH/PTHrP modulating domain.
  • a PTH/PTHrP modulating domain preferably the amino acid sequence of PTH/PTHrP modulating domains of PTH and /or PTHrP, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above
  • a vehicle such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred
  • Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter.
  • Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.
  • Such peptides typically will be antagonists of both PTH and PTHrP, although such techniques can be used to generate peptide sequences that serve as selective inhibitors (e.g., inhibitors of PTH but not PTHrP).
  • PTH and PTHrP modulators which comprises: a) selecting at least one peptide that binds to the PTH-1 or PTH-2 receptor; and b) covalently linking said peptide to a vehicle.
  • Step (a) is preferably carried out by selection from the peptide sequences in Tables 1A, IB, and 2 hereinafter or from phage display, RNA-peptide screening, or the other techniques mentioned herein.
  • the compounds of this invention may be prepared by standard synthetic methods, recombinant DNA techniques, or any other methods of preparing peptides and fusion proteins.
  • Compounds of this invention that encompass non-peptide portions may be synthesized by standard organic chemistry reactions, in addition to standard peptide chemistry reactions when applicable.
  • the primary use contemplated for the compounds of this invention is as therapeutic or prophylactic agents.
  • the vehicle-linked peptide may have activity comparable to — or even greater than — the natural ligand mimicked by the peptide.
  • the compounds of this invention may be used for therapeutic or prophylactic purposes by formulating them with appropriate pharmaceutical carrier materials and administering an effective amount to a patient, such as a human (or other mammal) in need thereof.
  • Other related aspects are also included in the instant invention.
  • molecules comprising PTH/PTHRP modulating domains having a shortened PTH C- terminal sequence such as PTH-(l-28) or (1-34).
  • FIG. 1 shows exemplary Fc dimers that may be derived from an IgGl antibody.
  • Fc in the figure represents any of the Fc variants within the meaning of “Fc domain” herein.
  • X 1 " and “X 2 " represent peptides or linker-peptide combinations as defined hereinafter.
  • the specific dimers are as follows:
  • IgGl antibodies typically have two disulfide bonds at the hinge region between the constant and variable domains.
  • the Fc domain in Figure 1A may be formed by truncation between the two disulfide bond sites or by substitution of a cysteinyl residue with an unreactive residue (e.g., alanyl).
  • the Fc domain is linked at the C-terminus of the peptide.
  • This Fc domain may be formed by truncation of the parent antibody to retain both cysteinyl residues in the Fc domain chains or by expression from a construct including a sequence encoding such an Fc domain.
  • the Fc domain is linked at the C- terminus of the peptide.
  • Noncovalent dimers This Fc domain may be formed by elimination of the cysteinyl residues by either truncation or substitution. One may desire to eliminate the cysteinyl residues to avoid impurities formed by reaction of the cysteinyl residue with cysteinyl residues of other proteins present in the host cell. The noncovalent bonding of the Fc domains is sufficient to hold together the dimer. Other dimers may be formed by using Fc domains derived from different types of antibodies (e.g., IgG2, IgM).
  • Figure 2 shows the structure of additional compounds of the invention.
  • Figure 2A shows a single chain molecule and may also represent the DNA construct for the molecule.
  • Figure 2B shows a dimer in which the linker-peptide portion is present on only one chain of the dimer.
  • Figure 2C shows a dimer having the peptide portion on both chains.
  • the dimer of Figure 2C will form spontaneously in certain host cells upon expression of a DNA construct encoding the single chain as shown in Figure 3. In other host cells, the cells could be placed in conditions favoring formation of dimers or the dimers can be formed in vitro.
  • Figure 3 shows exemplary nucleic acid and amino acid sequences (SEQ ID NOS: 1 and 2, respectively) of human IgGl Fc that may be used in this invention.
  • Figure 4 shows the calcemic response of normal mice to PTH-(l-34) and to PTH-(l-34)-Fc.
  • Mice were challenged with vehicle (PBS, -X-), or with PTH-(l-34) (open symbols) or with PTH-(l-34)-Fc (closed symbols).
  • Doses were 156 nmol/kg (circles), 469 nmol/kg (triangles) or 1,560 nmol/kg (squares). Data represent group means, n - 6 mice/group.
  • Figure 5 shows that [AsnlO,Leull]PTHrP-(7-34)-Fc inhibits the calcemic response of normal mice to PTHrP.
  • mice Normal male mice were injected SC with vehicle (PBS, circles) or with human PTHrP-(l-34) at 0.5 mg/kg (squares). PTHrP-challenged mice were then immediately injected SC with [AsnlO / Leull]PTHrP-(7-34)-Fc at 10 mg/kg (triangles) or 30 mg/kg (diamonds). Data represent group means, with an n of 6 mice /group.
  • Figure 6 shows the effect of [AsnlO,Leull]PTHrP-(7-34)-Fc on chronic hypercalcemia induced by PTH-(l-34)-Fc.
  • Normal male mice were challenged once by SC injection with PTH-(l-34)-Fc (30 mg/kg) (open circles), or with vehicle (PBS, open squares).
  • PTH ⁇ (l-34)-Fc- challenged mice were treated once, at the time of challenge, with [AsnlO,Leull]PTHrP-(7-34)-Fc at 10 (closed triangle), 30 (closed circle), or 100 mg/kg (closed square).
  • Figure 7 shows cAMP accumulation in ROS 17/2.8 rat osteoblast- like cells. Cultures were treated with the phosphodiesterase inhibitor IBMX and then challenged for 15 minutes with various PTH fragments. cAMP was measured by ELISA.
  • Figure 8 shows the effects of single treatments on clinical chemistry. Peripheral blood was obtained daily for 3 days following single subcutaneous injections of the indicated compounds.
  • Figure 8A shows total serum calcium
  • Figure 8B alkaline phosphatase (AP), a marker of osteoblast activity
  • Figure 8C tartrate-resistant acid phosphatase (TRAP), a marker of osteoclast activity
  • Figure 8D AP:TRAP ratio, an index of relative osteoblas: osteoclast activity.
  • Figure 9 shows the effects of PTH constructs on bone mineral density.
  • Peripheral quantitative computed tomography pQCT was performed on the proximal tibial metaphysis of mice on day 15, after injections of PTH constructs on day 0, 5 and 10.
  • Figure 10 shows the effect of twice-weekly PTH-(l-34)-Fc versus daily PTH-(l-34) on tibial, trabecular, and cortical bone mineral density (BMD).
  • Daily PTH [PTH-(l-34)] was given at 80 ⁇ g/kg/day (20 nmol/kg/day).
  • Figure 11 shows the effects of twice-weekly treatment on BMD and serum calcium in aged ovariectomized (OVX) rats. Eleven months after OVX, rats were treated twice per week with phosphate-buffered saline (PBS, vehicle) or with APD (0.5 mg/kg) or with PTH-(l-34)-Fc (50 nmol/kg). DEXA was performed weekly. Blood was drawn 24 hours after the second weekly injection, when the calcemic effects of PTH-Fc are typically maximal.
  • PBS phosphate-buffered saline
  • APD 0.5 mg/kg
  • PTH-(l-34)-Fc 50 nmol/kg
  • Figure 12 shows the effect of a single subcutaneous injection of PTH-(l-34)-Fc into OVX cynomologus monkeys.
  • Serum was analyzed for total calcium.
  • the dotted line indicates the threshold for hypercalcemia, based on an elevation of calcium greater than three standard deviations above the normal mean, on two or more consecutive timepoints.
  • Figure 13 shows SDS-PAGE analysis of representative samples of purified PEG-PTH (1-34) conjugate prepared from cysteine 27 PTH (1-34) analog and 5 kD, 10 kD, 20 kD and 30 kD linear PEG polymers, a 40 kD branched polymer and the 8 kD bis-functional polymer respectively.
  • Figures 14A through 14D show cAMP response of murine MC3T3-
  • FIG. 15 shows the hypercalcemic response of young male BDFl mice to various PTH constructs. All treatments were single subcutaneous injections of 300 nmol/kg (PTH referent).
  • Figure 16 shows the hypercalcemic response of young male BDFl mice to a single subcutaneous injection of PTH-(l-34)-Fc or PEG-PTH constructs. Blood ionized calcium was measured at the timepoints indicated in the figure.
  • Figure 17 shows the effect of PTH-(l-34)-Fc or C27-30K PEG-PTH on tibial bone mineral density (BMD) in adult male BDFl mice. Mice were treated by subcutaneous, injection either once or twice per week for 4 weeks. The symbol # indicates significant difference from vehicle (PBS)- treated mice, by two-way ANOVA.
  • a compound may include additional amino acids on either or both of the N- or C- termini of the given sequence. Of course, these additional amino acids should not significantly interfere with the activity of the compound.
  • amino acid residue refers to amino acid residues in D- or L- form having sidechains comprising acidic groups. Exemplary acidic residues include D and E.
  • aromatic residue refers to amino acid residues in D- or L- form having sidechains comprising acidic groups. Exemplary acidic residues include D and E.
  • aromatic residue refers to amino acid residues in D- or L- form having sidechains comprising acidic groups. Exemplary acidic residues include D and E.
  • aromatic residue refers to amino acid residues in D- or
  • L-form having sidechains comprising aromatic groups Exemplary aromatic residues include F, Y, and W.
  • basic residue refers to amino acid residues in D- or L- form having sidechains comprising basic groups. Exemplary basic residues include H, K, and R.
  • hydrophilic residue and “Haa” refer to amino acid residues in D- or L-form having sidechains comprising at least one hydrophilic functional group or polar group.
  • exemplary hydrophilic residues include C, D, E, H, K, N, Q, R, S, and T.
  • lipophilic residue and “Laa” refer to amino acid residues in D- or L-form having sidechains comprising uncharged, aliphatic or aromatic groups.
  • Exemplary lipophilic sidechains include F, I, L, M, V, W, and Y.
  • Alanine (A) is amphiphilic — it is capable of acting as a hydrophilic or lipophilic residue. Alanine, therefore, is included within the definition of both "lipophilic residue” and “hydrophilic residue.”
  • nonfunctional residue refers to amino acid residues in D- or L-form having sidechains that lack acidic, basic, or aromatic groups.
  • exemplary nonfunctional amino acid residues include M, G, A, V, I, L and norleucine (Nle).
  • vehicle refers to a molecule that prevents degradation and/or increases half-life, reduces toxicity, reduces immunogenicity, or increases biological activity of a therapeutic protein.
  • exemplary vehicles include an Fc domain (which is preferred) as well as a linear polymer (e.g., polyethylene glycol (PEG), polylysine, dextran, etc.); a branched-chain polymer (see, for example, U.S. Patent No.
  • lipid 4,289,872 to Denkenwalter et al., issued September 15, 1981; 5,229,490 to Tarn, issued July 20, 1993; WO 93/21259 by Frechet et al., published 28 October 1993); a lipid; a cholesterol group (such as a steroid); a carbohydrate or oligosaccharide (e.g., dextran); human serum albumin (HSA) and related molecules; transtheratin (TTR) and related molecules; or any natural or synthetic protein, polypeptide or peptide that binds to a salvage receptor.
  • HSA human serum albumin
  • TTR transtheratin
  • the ter “native Fc” refers to molecule or sequence comprising the sequence of a non-antigen-binding fragment resulting from digestion of whole antibody, whether in monomeric or multimeric form.
  • the original immunoglobulin source of the native Fc is preferably of human origin and may be any of the immunoglobulins, although IgGl and IgG2 are preferred.
  • Native Fc's are made up of monomeric polypeptides that may be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association.
  • the number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, IgE) or subclass (e.g., IgGl, IgG2, IgG3, IgAl, IgGA2).
  • class e.g., IgG, IgA, IgE
  • subclass e.g., IgGl, IgG2, IgG3, IgAl, IgGA2
  • One example of a native Fc is a disulfide- bonded dimer resulting from papain digestion of an IgG (see Ellison et al. (1982), Nucleic Acids Res. 10: 4071-9) .
  • native Fc as used herein is generic to the monomeric, dimeric, and multimeric forms.
  • Fc variant refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn.
  • International applications WO 97/34631 (published 25 September 1997) and WO 96/32478 describe exemplary Fc variants, as well as interaction with the salvage receptor, and are hereby incorporated by reference in their entirety.
  • Fc variant comprises a molecule or sequence that is humanized from a non-human native Fc.
  • a native Fc comprises sites that may be removed because they provide structural features or biological activity that are not required for the fusion molecules of the present invention.
  • Fc variant comprises a molecule or sequence that lacks one or more native Fc sites or residues that affect or are involved in (1) disulfide bond formation, (2) incompatibility with a selected host cell (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).
  • Fc variants are described in further detail hereinafter.
  • the term "Fc domain” encompasses native Fc and Fc variant molecules and sequences as defined above.
  • Fc domain includes molecules in monomeric or multimeric form, whether digested from whole antibody or produced by other means.
  • multimer as applied to Fc domains or molecules comprising Fc domains refers to molecules having two or more polypeptide chains associated covalently, noncovalently, or by both covalent and non-covalent interactions.
  • IgG molecules typically form dimers; IgM, pentamers; IgD, dimers; and IgA, monomers, dinners, trimers, or tetramers. Multimers may be formed by exploiting the sequence and resulting activity of the native Ig source of the Fc or by derivatizing (as defined below) such a native Fc.
  • dimer as applied to Fc domains or molecules comprising Fc domains refers to molecules having two polypeptide chains associated covalently or non-covalently.
  • exemplary dimers within the scope of this invention are as shown in Figures 1 and 2.
  • the terms "derivatizing” and “derivative” or “derivatized” comprise processes and resulting compounds respectively in which (1) the compound has a cyclic portion; for example, cross-linking between cysteinyl residues within the compound; (2) the compound is cross-linked or has a cross-linking site; for example, the compound has a cysteinyl residue and thus forms cross-linked dimers in culture or in vivo; (3) one or more peptidyl linkage is replaced by a non-peptidyl linkage; (4) the N- terminus is replaced by -NRR 1 , NRC(0)R ⁇ -NRC(0)OR 1 , -NRS(0) 2 R 1 , - NHC(0)NHR, a succinimide group, or substituted or unsubstituted benzyloxycarbonyl-NH-, wherein R and R 1 and the ring substituents are as defined hereinafter; (5) the C-terminus is replaced by -C(0)R 2 or -NR 3 R 4 wherein R 2
  • peptide refers to molecules of 1 to 85 amino acids, with molecules of 5 to 34 amino acids preferred.
  • exemplary peptides may comprise the PTH/PTHrP modulating domain of a naturally occurring molecule or comprise randomized sequences.
  • randomized refers to fully random sequences (e.g., selected by phage display methods or RNA-peptide screening) and sequences in which one or more residues of a naturally occurring molecule is replaced by an amino acid residue not appearing in that position in the naturally occurring molecule.
  • Exemplary methods for identifying peptide sequences include phage display, E. coli display, ribosome display, RNA-peptide screening, chemical screening, and the like.
  • PTH/PTHrP modulating domain refers to any amino acid sequence that binds to the PTH-1 receptor and /or the PTH-2 receptor and comprises naturally occurring sequences or randomized sequences. Exemplary PTH/PTHrP modulating domains can be identified or derived as described in the references listed for Tables 1A and 2, which are hereby incorporated by reference in their entirety.
  • PTH agonist refers to a molecule that binds to PTH-1 or PTH-2 receptor and increases or decreases one or more PTH activity assay parameters as does full-length native human parathyroid hormone.
  • An exemplary PTH activity assay is disclosed in Example 1.
  • PTH antagonist refers to a molecule that binds to PTH-1 or PTH-2 receptor and blocks or prevents the normal effect on those parameters by full length native human parathyroid hormone.
  • An exemplary PTH activity assay is disclosed in Example 2.
  • the term “bone resorption inhibitor” refers to such molecules as determined by the assays of Examples 4 and 11 of WO 97/23614:, which is hereby incorporated by reference in its entirety. Exemplary bone resorption inhibitors include OPG and OPG-L antibody, which are described in WO 97/23614 and W098/46751, respectively, which are hereby incorporated by reference in their entirety.
  • physiologically acceptable salts of the compounds of this invention are also encompassed herein.
  • physiologically acceptable salts is meant any salts that are known or later discovered to be pharmaceutically acceptable. Some specific examples are: acetate; trifluoroacetate; hydrohalides, such as hydrochloride and hydrobromide; sulfate; citrate; tartrate; glycolate; and oxalate. Structure of compounds In General.
  • PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2. Other information on PTH and PTH and PTHrP receptor binding amino acid sequences are described in Tables 1A, IB, and 2.
  • the present inventors identified in particular preferred sequences derived from PTH and PTHrP. These sequences can be randomized through the techniques mentioned above by which one or more amino acids may be changed while maintaining or even improving the binding affinity of the peptide.
  • the peptide may be attached to the vehicle through the peptide's C-terminus.
  • the vehicle-peptide molecules of this invention may be described by the following formula I: I and multimers thereof, wherein:
  • F 1 is a vehicle (preferably a PEG molecule) and is attached at the C- terminus of P 1 -(L 1 ) a or through a sidechain at any residue from residue 14 through the C-terminal residue;
  • PHs a sequence of a PTH/PTHrP modulating domain
  • L 1 is a linker
  • a is 0 or 1.
  • Peptides Any number of peptides may be used in conjunction with the present invention. Peptides may comprise part of the sequence of naturally occurring proteins, may be randomized sequences derived from the sequence of the naturally occurring proteins, or may be wholly randomized sequences. Phage display and RNA-peptide screening, in particular, are useful in generating peptides for use in the present invention.
  • a PTH/PTHrP modulating domain sequence particularly of interest is of the formula II X ⁇ HX ⁇ X ⁇ KX ⁇ X ⁇ X 1 ⁇
  • X N is absent or is X 3 X 4 X 5 X 6 X 7 , X 2 X 3 X 4 X 5 X 6 X 7 , X 1 X 2 X 3 X*X S X 6 X 7 , or YX'XWX ⁇ X 7 ;
  • X I is an amino acid residue (nonfunctional, hydrophilic or aromatic residue preferred; A, S or Y preferred);
  • X 2 is an amino acid residue (nonfunctional residue preferred, V most preferred);
  • X 3 is an amino acid residue (hydrophilic residue preferred, S most preferred);
  • X 4 is an amino acid residue (acidic residue preferred, E most preferred);
  • X 5 is an amino acid residue (nonfunctional or basic residue preferred, H or I most preferred);
  • X 6 is an amino acid residue (acidic or hydrophilic residue preferred, Q or E most preferred);
  • X 7 is an amino acid residue (nonfunctional or aromatic residue preferred, L or F most preferred);
  • X 8 is an amino acid residue (nonfunctional residue preferred, M or
  • X 10 is an amino acid residue (an acidic or hydrophilic residue preferred, N or D most preferred);
  • X II is an amino acid residue (nonfunctional or basic residue preferred, L, R, or K most preferred);
  • X 12 is an amino acid residue (nonfunctional or aromatic residue preferred, G, F, or W most preferred);
  • X 14 is an amino acid residue (basic or hydrophilic residue preferred, H or S most preferred); X 15 is an amino acid residue (nonfunctional residue preferred, with
  • X 16 is an amino acid residue (nonfunctional or hydrophilic residue preferred, Q, N, S, or A most preferred);
  • X 17 is an amino acid residue (acidic, hydrophilic, or nonfunctional residue preferred; S, D, or L most preferred);
  • X 18 is an amino acid residue (nonfunctional residue preferred, M, L, V or Nle most preferred); X 19 is an amino acid residue (acidic or basic residue preferred, E or
  • X 21 is an amino acid residue (nonfunctional residue or basic residue preferred; V, M, R, or Nle most preferred);
  • X 22 is an amino acid residue (hydrophilic, acidic, or aromatic residue preferred, E or F most preferred);
  • X 23 is an aromatic or lipophilic residue (W or F preferred);
  • X 24 is a lipophilic residue (L preferred);
  • X 25 is an amino acid residue (hydrophilic or basic residue preferred, R ox H most preferred); X 26 is an amino acid residue (hydrophilic or basic residue preferred,
  • X 27 is an amino acid residue (lipophilic, basic, or nonfunctional residue preferred, K or L most preferred);
  • X 28 is an amino acid residue (lipophilic or nonfunctional residue preferred, L or I most preferred);
  • X c is absent or is X 29 , X 29 X 30 , X 29 X 30 X 31 , X 29 X 3Q X 31 X 32 , X 29 X 30 X 31 X 32 X 33 ,
  • X 29 is an amino acid residue (hydrophilic or nonfunctional residue preferred, Q or A most preferred);
  • X 30 is an amino acid residue (hydrophilic or acidic residue preferred, D or E most preferred);
  • X 31 is an amino acid residue (lipophilic or nonfunctional residue preferred, V or I most preferred);
  • X 32 is an amino acid residue (basic residue preferred, H most preferred);
  • X 33 is an amino acid residue (hydrophilic residue preferred, N or T most preferred);
  • X 34 is an amino acid residue (nonfunctional or aromatic residue preferred, A, F or Y most preferred);
  • X 35 is an amino acid residue (acidic residue preferred, E most preferred);
  • X 36 is an amino acid residue (aromatic residue preferred, Y most preferred) ; provided that one or more of X 14 through X 36 is a cysteine residue.
  • a preferred PTH/PTHrP modulating domain sequence formula is III
  • J N is absent or is selected from J JWJ 6 , jr ⁇ j 6 , J 3 J 4 J 5 J 6 ;
  • J 1 is an amino acid residue (nonfunctional, hydrophilic, or aromatic residue preferred; A, S or Y most preferred);
  • J 2 is an amino acid residue (nonfunctional residue preferred, V most preferred);
  • J 3 is an amino acid residue (hydrophilic residue preferred, S most preferred);
  • J 4 is an amino acid residue (acidic residue preferred, E most preferred);
  • J s is' an amino acid residue (nonfunctional residue preferred, I most preferred);
  • J 6 is an amino acid residue (basic residue preferred, Q preferred); J 7 is an amino acid residue (nonfunctional or aromatic residue preferred, L or F most preferred);
  • J 8 is an amino acid residue (nonfunctional residue preferred, M or Nle most preferred); J 12 is an amino acid residue (nonfunctional or aromatic residue preferred, G or W most preferred);
  • J 16 is an amino acid residue (nonfunctional or hydrophilic residue preferred, N, S, or A most preferred);
  • J 18 is an amino acid residue (nonfunctional residue preferred, M, Nle, L, or V most preferred);
  • J 19 is an acidic or basic residue (E or R preferred);
  • J 21 is an amino acid residue (nonfunctional residue preferred, V, M, or Nle most preferred);
  • J 29 is an amino acid residue (hydrophilic or nonfunctional residue preferred, Q or A most preferred);
  • J 30 is an amino acid residue (hydrophilic or acidic residue preferred, D or E most preferred);
  • J 31 is an amino acid residue (lipophilic or nonfunctional residue preferred, V or I most preferred);
  • J 32 is an amino acid residue (basic residue preferred, H most preferred);
  • J 33 is an amino acid residue (acidic residue preferred, N most preferred); J 34 is an amino acid residue (aromatic residue preferred, F or Y most preferred); provided that one or more of J 14 through the C-terminal residue is a cysteine residue. From the formula of SEQ ID NO: 4, peptides appearing in Table 1A or IB below are most preferred.
  • PTH/PTHrP modulating domain sequence is IV O N LHO 10 O 11 O 12 KSIO 15 O 16 LRRRFO 23 LHHLIO c
  • O N is absent or is YO'O ⁇ O WO 7 , O ⁇ O ⁇ O ⁇ O 7 , 0 2 0 3 0 4 0 5 0 6 0 7 , 0 3 0 4 0 5 0 6 0 7 , 0 4 0 5 0 6 0 7 , 0 5 0 6 0 7 , 0 6 0 7 , or O 7 ;
  • O 1 is an amino acid residue (nonfunctional residue preferred, A most preferred);
  • 0 2 is an amino acid residue (nonfunctional residue preferred, V most preferred);
  • 0 3 is an amino acid residue (hydrophilic residue preferred, S most preferred);
  • 0 4 is an amino acid residue (acidic residue preferred, E most preferred);
  • 0 5 is an amino acid residue (basic or nonfunctional residue preferred, H or I preferred); O 6 is an amino acid residue (hydrophilic residue preferred, Q most preferred);
  • O 7 is an amino acid residue (nonfunctional residue preferred, L most preferred);
  • O 10 is an amino acid residue (acidic or hydrophilic residue preferred, N or D most preferred);
  • O u is an amino acid residue (basic or nonfunctional residue preferred, K or L most preferred);
  • O 12 is an amino acid residue (aromatic or nonfunctional residue preferred, G, F, or W most preferred); 0 15 is an amino acid residue (hydrophilic or nonfunctional residue preferred, I or S most preferred);
  • 0 16 is an amino acid residue (hydrophilic residue preferred, Q or N most preferred);
  • O 17 is an amino acid residue (acidic or nonfunctional residue preferred, D or L most preferred);
  • O 23 is an amino acid residue (aromatic residue preferred, with F or W most preferred);
  • O c is absent or is O 29 , 0 29 0 30 , 0 29 O 30 O 31 , 0 29 O 30 O 31 O 32 , 0 29 O 30 O 31 O 32 O 33 , O 29 O 30 O 31 O 32 O 33 O 34 , 0 29 O 30 O 31 O 32 O 33 O 34 O 35 , or O 29 O 30 O 31 O 32 O 33 O 34 O 35 O 36 ; and O 29 through O 36 are each independently amino acid residues; provided that one or more of O 14 through the C-terminal residue is a cysteine residue.
  • Exemplary peptide sequences for this invention appear in Tables 1A, IB and 2 below. These peptides may be prepared as described in the cited references or in U.S. Pat. Nos. 4,423,037, 4,968,669, 5,001,22, and 6,051,686, each of which is hereby incorporated by reference in its entirety, or as described hereinafter. Molecules of this invention incorporating these peptide sequences may be prepared by methods known in the art or as described hereinafter. Single letter amino acid abbreviations are used. Any of these peptides may be linked in tandem (i.e., sequentially), with or without linkers.
  • Any peptide containing a cysteinyl residue may be cross- linked with another Cys-containing peptide, either or both of which may be linked to a vehicle. Any peptide having more than one Cys residue may form an intrapeptide disulfide bond, as well. Any of these peptides may be derivatized as described hereinafter. Table 1A— PTH/PTHrP modulating domains based on PTH
  • PTH/PTHrP modulating domain has the sequence of the peptide known as TIP39:
  • TIP39 is described by Usdin et al. (1999), Nature Neurosci. 2(11): 941-3; Usdin et al- (1996), Endocrinology 137(10): 4285-97; Usdin et al- (1995), L Biol. Chem. 270(26): 15455-8; Usdin et al. (1999), Endocrinol. 140(7): 3363- 71.
  • useful PTH/PTHrP modulating domain sequences may result from conservative and/or non-conservative modifications of the amino acid sequences of SEQ ID NOS: 3, 4, 5, TIP39, or the sequences listed in Tables 1A, IB, and 2.
  • useful PTH/PTHrP modulating domains further comprise molecules in which any residue at position 14 through the C-terminal amino acid of any sequence in Tables 1A and 2 is substituted with a cysteine residue to provide an attachment site for a polymer (PEG preferred). Cysteine substitutions at position 27 through the C-terminal peptide are preferred.
  • Conservative modifications will produce peptides having functional and chemical characteristics similar to those of the PTH or PTHrP peptide from which such modifications are made.
  • substantial modifications in the functional and/or chemical characteristics of the peptides may be accomplished by selecting substitutions in the amino acid sequence that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the size of the molecule.
  • a "conservative amino acid substitution” may involve a substitution of a native amino acid residue with a normative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position.
  • any native residue in the polypeptide may also be substituted with alanine, as has been previously described for "alanine scanning mutagenesis” (see, for example, MacLennan et al, 1998, Acta Physiol. Scand. Suppl. 643:55-67; Sasaki et al., 1998, Adv. Biophys. 35:1-24, which discuss alanine scanning mutagenesis).
  • Desired amino acid substitutions can be determined by those skilled in the art at the time such substitutions are desired.
  • amino acid substitutions can be used to identify important residues of the peptide sequence, or to increase or decrease the affinity of the peptide or vehicle-peptide molecules (see preceding formulae) described herein.
  • Exemplary amino acid substitutions are set forth in Table 3.
  • conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems.
  • naturally occurring residues may be divided into classes based on common sidechain properties that may be useful for modifications of sequence.
  • non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.
  • Such substituted residues may be introduced into regions of the peptide that are homologous with non-human orthologs, or into the non-homologous regions of the molecule.
  • one may also make modifications using P or G for the purpose of influencing chain orientation.
  • hydropathic index of amino acids may be considered.
  • Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine /cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (- 3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
  • hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1); glutamate (+3.0 ⁇ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ⁇ 1); alanine (-0.5); histidine (-0.5); cysteine (- 1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).
  • a skilled artisan will be able to determine suitable variants of the polypeptide as set forth in the foregoing sequences using well known techniques. For identifying suitable areas of the molecule that may be changed without destroying activity, one skilled in the art may target areas not believed to be important for activity. For example, when similar polypeptides with similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of a peptide to similar peptides. With such a comparison, one can identify residues and portions of the molecules that are conserved among similar polypeptides. It will be appreciated that changes in areas of a peptide that are not conserved relative to such similar peptides would be less likely to adversely affect the biological activity and/or structure of the peptide.
  • One skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to that structure in similar polypeptides. In view of that information, one skilled in the art may predict the alignment of amino acid residues of a peptide with respect to its three dimensional structure. One skilled in the art may choose not to make radical changes to amino acid residues predicted to be on the surface of the protein, since such residues may be involved in important interactions with other molecules. Moreover, one skilled in the art may generate test variants containing a single amino acid substitution at each desired amino acid residue. The variants can then be screened using activity assays know to those skilled in the art. Such data could be used to gather information about suitable variants.
  • One method of predicting secondary structure is based upon homology modeling. For example, two polypeptides or proteins which have a sequence identity of greater than 30%, or similarity greater than 40% often have similar structural topologies.
  • the recent growth of the protein structural data base (PDB) has provided enhanced predictability of secondary structure, including the potential number of folds within a polypeptide's or protein's structure. See Holm et al., Nucl. Acid. Res., 27(1): 244-247 (1999). It has been suggested (Brenner et al, Curr. Op. Struct. Biol., 7(3): 369-376 (1997)) that there are a limited number of folds in a given polypeptide or_protein and that once a critical number of structures have been resolved, structural prediction will gain dramatically in accuracy.
  • Additional methods of predicting secondary structure include “threading” (Jones, D., Curr. Opin. Struct. Biol., 7(3): 377-87 (1997); Sippl et al.. Structure, 4(1): 15-9 (1996)), “profile analysis” (Bowie et al., Science, 253: 164-170 (1991); Gribskov et al, Meth. Enzym., 183: 146-159 (1990); Gribskov et al, Proc. Nat. Acad. Sci., 84(13): 4355-8 (1987)), and “evolutionary linkage” (See Home, supra, and Brenner, supra). Vehicles.
  • This invention requires the presence of at least one vehicle (F 1 ) attached to a peptide through the C-terminus or a sidechain of one of the amino acid residues.
  • Multiple vehicles may also be used; e.g., an Fc at the C-terminus and a PEG group at a sidechain.
  • Fc domain An Fc domain is the preferred vehicle.
  • the Fc domain may be fused to the C terminus of the peptides.
  • Fc variants are suitable vehicles within the scope of this invention.
  • a native Fc may be extensively modified to form an Fc variant in accordance with this invention, provided binding to the salvage receptor is maintained; see, for example WO 97/34631 and WO 96/32478.
  • the inserted or substituted residues may also be altered amino acids, such as peptidomimetics or D- amino acids.
  • Fc variants may be desirable for a number of reasons, several of which are described below.
  • Exemplary Fc variants include molecules and sequences in which: 1. Sites involved in disulfide bond formation are removed. Such removal may avoid reaction with other cysteine-containing proteins present in the host cell used to produce the molecules of the invention.
  • the cysteine-containing segment at the N-terminus may be truncated or cysteine residues may be deleted or substituted with other amino acids (e.g., alanyl, seryl).
  • one may truncate the N- terminal 20-amino acid segment of SEQ ID NO: 2 or delete or substitute the cysteine residues at positions 7 and 10 of SEQ ID NO: 2.
  • a native Fc is modified to make it more compatible with a selected host cell. For example, one may remove the PA sequence near the N- terminus of a typical native Fc, which may be recognized by a digestive enzyme in E. coli such as proline iminopeptidase. One may also add an N-terminal methionine residue, especially when the molecule is expressed recombinantly in a bacterial cell such as E. coli.
  • the Fc domain of SEQ ID NO: 2 is one such Fc variant.
  • a portion of the N-terminus of a native Fc is removed to prevent N- terminal heterogeneity when expressed in a selected host cell. For this purpose, one may delete any of the first 20 amino acid residues at the
  • N-terminus particularly those at positions 1, 2, 3, 4 and 5.
  • Residues that are typically glycosylated may confer cytolytic response. Such residues may be deleted or substituted with unglycosylated residues (e.g., alanine).
  • Sites involved in interaction with complement such as the Clq binding site, are removed. For example, one may delete or substitute the EKK sequence of human IgGl. Complement recruitment may not be advantageous for the molecules of this invention and so may be avoided with such an Fc variant.
  • a native Fc may have sites for interaction with certain white blood cells that are not required for the fusion molecules of the present invention and so may be removed.
  • the ADCC site is removed. ADCC sites are known in the art; see, for example, Molec. Immunol. 29 (5): 633-9 (1992) with regard to ADCC sites in IgGl. These sites, as well, are not required for the fusion molecules of the present invention and so may be removed.
  • the native Fc When the native Fc is derived from a non-human antibody, the native Fc may be humanized. Typically, to humanize a native Fc, one will substitute selected residues in the non-human native Fc with residues that are normally found in human native Fc. Techniques for antibody humanization are well known in the art.
  • Preferred Fc variants include the following.
  • the leucine at position 15 may be substituted with glutamate; the glutamate at position 99, with alanine; and the lysines at positions 101 and 103, with alanines.
  • one or more tyrosine residues can be replaced by phenyalanine residues.
  • An alternative vehicle would be a protein, polypeptide, peptide, antibody, antibody fragment, or small molecule (e.g., a peptidomimetic compound) capable of binding to a salvage receptor.
  • a polypeptide as described in U.S. Pat. No. 5,739,277, issued April 14, 1998 to Presta et al.
  • Peptides could also be selected by phage display or RNA-peptide screening for binding to the FcRn salvage receptor.
  • salvage receptor-binding compounds are also included within the meaning of "vehicle” and are within the scope of this invention.
  • Such vehicles should be selected for increased half-life (e.g., by avoiding sequences recognized by proteases) and decreased immunogenicity (e.g., by favoring non-immuno genie sequences, as discovered in antibody humanization).
  • PCT Patent Cooperation Treaty
  • WO 96/11953 entitled “N- Terminally Chemically Modified Protein Compositions and Methods,” herein incorporated by reference in its entirety.
  • This PCT publication discloses, among other things, the selective attachment of water soluble polymers to the N-terminus of proteins.
  • a preferred polymer vehicle is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the chemical modification of therapeutic proteins with polyethylene glycol (PEG) has been broadly applied to improve the in vivo efficacy of protein drugs. See “Protein Conjugates” chapter in Harris, et al., American Chemical Society pp. 118-216 (1997). PEGylation achieves this effect by extending the drug's circulating half-life, increasing its solubility and in some cases, reducing the drug's toxicity and immunogenicity.
  • the PEG group may be of any convenient molecular weight and may be linear or branched. The average molecular weight of the PEG will preferably range from about 2 kiloDalton ("kD") to about 100 kD.
  • the PEG group may also be attached to more than one therapeutic molecule; for example, in a peptide-PEG-peptide configuration.
  • Two PEG molecules may also be attached to multiple sites or to a single site of a therapeutic molecule; for example, two PEG molecules attached to a cysteine sidechain through a linker.
  • the average molecular weight of the PEG will preferably range from about 2 kiloDalton ("kD") to about 100 kDa, more preferably from about 5 kDa to about 50 kDa, most preferably from about 5 kDa, 20 kDa, or 30 kDa.
  • linear monomethoxy PEG-maleimides of molecular weights in the range of 5 - 30 kDa are preferred, with 20-30 kDa polymers most preferred.
  • a 40 kDa branched PEG-maleimide comprised of two 20 kDa polymer "arms" joined through a linker at the peptide attachment site.
  • Another preferred embodiment employs an 8 kDa bis-functional PEG-(maleimide) 2 which can be used to generate a peptide-PEG-peptide configuration.
  • the PEG groups can generally be attached to the compounds of the invention via acylation or reductive alkylation through a reactive group on the PEG moiety (e.g., an aldehyde, amino, thiol, or ester group) to a reactive group on the inventive compound (e.g., an aldehyde, amino, or ester group).
  • a useful strategy for the PEGylation of synthetic peptides consists of combining, through forming a conjugate linkage in solution, a peptide and a PEG moiety, each bearing a special functionality that is mutually reactive toward the other.
  • the peptides can be easily prepared with conventional solid phase synthesis.
  • the peptides are "preactivated” with an appropriate functional group at a specific site.
  • the precursors are purified and fully characterized prior to reacting with the PEG moiety. Ligation of the peptide with PEG usually takes place in aqueous phase and can be easily monitored by reverse phase analytical HPLC.
  • the PEGylated peptides can be easily purified by preparative HPLC and characterized by analytical HPLC, amino acid analysis and laser desorption mass spectrometry.
  • Solid phase synthesis is also useful to prepare molecules PEGylated through an available amino group (e.g., a lysine sidechain) using an orthogonal protection strategy.
  • the peptide is synthesized with removable protecting groups (e.g., Dde for lysine sidechains) attached to the amino groups and any other reactive groups that are not selected for PEGylation.
  • the synthesized peptide can then undergo a reaction resulting in PEGylation of the unprotected amino group.
  • the protecting groups on the other reactive groups can then be removed by conventional means. This technique is especially useful for PEGylation of one of the lysine residues of the PTH fragments mentioned herein.
  • the sidechain of one of the lysine residues at positions 13, 26, or 27 is left unprotected while the others comprise a Dde protecting group.
  • the Dde groups are selectively removed using 2% hydrazine in water for 5 to 30 minutes at room temperature.
  • Solid phase synthesis techniques may also be employed to prepare molecules having a PEG moiety at the C-terminus.
  • the molecule may comprise a PEG moiety linking it to a resin used for solid phase synthesis.
  • the synthesized molecule may then be cleaved from the resin such that the PEG moiety is retained with the peptide.
  • Site-directed approaches may be useful to maximize retention of biological activity while minimizing conjugate heterogeneity.
  • Site- directed PEGylation is typically achieved through a combination of recombinant protein techniques and selective conjugation chemistries.
  • site-directed mutagenesis is used to introduce unique amino acids with reactive functional groups into the polypeptide sequence at positions predicted to have minimal impact on protein activity Goodson, et al, Bio/Technology 8:343-346 (1990) and Tsutsumi, et al., Proc. Natl. Acad. Sci. 97:8548-8553 (2000).
  • Cysteine is the preferred residue for engineering directed conjugation sites because it is relatively scarce in proteins and the thiol sidechain is among the most reactive of the protein nucleophiles.
  • the mutagenic nucleic acid is introduced into a vector, which then is used to transfect a host cell (e.g., E. coli, which is preferred), and the peptide is expressed and isolated from the host cell.
  • a host cell e.g., E. coli, which is preferred
  • an activated monofunctional PEG polymer is prepared or obtained commercially.
  • activated PEG polymers available which react specifically with cysteine thiols, such as PEG-maleimide, -vinylsulfone, -iodoacetamide, -orthopyridyl- disulphide and -epoxides, among others, the PEG-maleimides are by far the most commonly used for conjugation.
  • cysteine-containing protein and activated PEG are combined under appropriate reaction conditions to promote formation of a PEG-protein conjugate which is subsequently purified and characterized.
  • PEG-maleimides are preferred PEGylating reagents, but PEGylation may also be achieved with PEG-vinylsulfones, PEG- orthopyridyl-disulphides and PEG-iodoacetamides or any other activated PEG that is selective for cysteine thiols.
  • cysteine residues are convenient substrates for PEGylation chemistry, as noted above, the PTH-(l-34) peptide and other peptides useful in this invention (e.g., see Tables 1A and 2) contains no natural Cys residues for PEG conjugation. Cys mutations can be introduced at any position, but structure-activity data suggests that C- terminal domain insertions or substitutions are preferred. In one preferred embodiment, cysteine residues were introduced into PTH-(l-34) by substituting Cys for Lysine at position 27, and/or by inserting Cys between histidine and asparagine at position 33.
  • Polysaccharide polymers are another type of water soluble polymer which may be used for protein modification and may be prepared by techniques generally as described above.
  • Dextrans are polysaccharide polymers comprised of individual subunits of glucose predominantly linked by c.1-6 linkages. The dextran itself is available in many molecular weight ranges, and is readily available in molecular weights from about 1 kD to about 70 kD.
  • Dextran is a suitable water soluble polymer for use in the present invention as a vehicle by itself or in combination with another vehicle (e.g., Fc). See, for example, WO 96/11953 and WO 96/05309.
  • linker is optional. When present, its chemical structure is not critical, since it serves primarily as a spacer.
  • the linker is preferably made up of amino acids linked together by peptide bonds.
  • the linker is made up of from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally occurring amino acids. Some of these amino acids may be glycosylated, as is well understood by those in the art.
  • the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine.
  • a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine.
  • preferred linkers are polyglycines (particularly (Gly) 4 , (Gly) s ), poly(Gly-Ala), and polyalanines.
  • Other specific examples of linkers are: (Gly) 3 Lys(Gly) 4 (SEQ ID NO: 6);
  • (Gly) 3 AsnGlySer(Gly) 2 (SEQ ID NO: 7); (Gly) 3 Cys(Gly) 4 (SEQ ID NO: 8); and GlyProAsnGlyGly (SEQ ID NO: 9).
  • (Gly) 3 Lys(Gly) 4 means Gly-Gly-Gly-Lys-Gly-Gly-Gly-Gly. Combinations of Gly and Ala are also preferred.
  • the linkers shown here are exemplary; linkers within the scope of this invention may be much longer and may include other residues.
  • Non-peptide linkers are also possible.
  • These alkyl linkers may further be substituted by any non-sterically hindering group such as lower alkyl (e.g., -C-) lower acyl, halogen (e.g., Cl, Br), CN, NH 2 , phenyl, eta.
  • An exemplary non-peptide linker is a PEG linker, VI
  • n is such that the linker has a molecular weight of 100 to 5000 kD, preferably 100 to 500 kD.
  • the peptide linkers may be altered to form derivatives in the same manner as described above.
  • the inventors also contemplate derivatizing the peptide and/or vehicle portion of the compounds.
  • Such derivatives may improve the solubility, absorption, biological half life, and the like of the compounds.
  • the moieties may alternatively eliminate or attenuate any undesirable side-effect of the compounds and the like.
  • Exemplary derivatives include compounds in which:
  • the compound or some portion thereof is cyclic.
  • the peptide portion may be modified to contain two or more Cys residues (e.g., in the linker), which could cyclize by disulfide bond formation.
  • the compound is cross-linked or is rendered capable of cross-linking between molecules.
  • the peptide portion may be modified to contain one Cys residue and thereby be able to form an intermolecular disulfide bond with a like molecule.
  • the compound may also be cross-linked through its C-terminus, as in the molecule shown below.
  • Non-peptidyl linkages are -CH 2 - carbamate [-CH 2 -OC(0)NR-], phosphonate , -CH 2 -sulfonamide [-CH 2 - S(0) 2 NR-], urea [-NHC(0)NH-], -CH 2 -secondary amine, and alkylated peptide [-C(0)NR 6 - wherein R 6 is lower alkyl] .
  • the N-terminus is derivarized. Typically, the N-terminus may be acylated or modified to a substituted amine.
  • Exemplary N-terminal derivative groups include -NRR 1 (other than -NH 2 ), -NRC(0)R 1 , -NRC(0)OR 1 , -NRS ⁇ R 1 , -NHC(0)NHR 1 , succinimide, or benzyloxycarbonyl-NH- (CBZ-NH-), wherein R and R 1 are each independently hydrogen or lower alkyl and wherein the phenyl ring may be substituted with 1 to 3 substituents selected from the group consisting of C.-C 4 alkyl, C.-C 4 alkoxy, chloro, and bromo.
  • the free C-terminus is derivatized. Typically, the C-terminus is esterified or amidated.
  • Exemplary C-terminal derivative groups include, for example, -C(0)R 2 wherein R 2 is lower alkoxy or -NR 3 R 4 wherein R 3 and R 4 are independently hydrogen or C.-C 8 alkyl (preferably C.-C 4 alkyl).
  • a disulfide bond is replaced with another, preferably more stable, cross-linking moiety (e.g., an alkylene). See, e.g., Bhatnagar et al.
  • One or more individual amino acid residues is modified.
  • Various derivatizing agents are known to react specifically with selected sidechains or terminal residues, as described in detail below.
  • Lysinyl residues and amino terminal residues may be reacted with succinic or other carboxylic acid anhydrides, which reverse the charge of the lysinyl residues.
  • suitable reagents for derivatizing alpha-amino- containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.
  • Arginyl residues may be modified by reaction with any one or combination of several conventional reagents, including phenylglyoxal, 2,3- butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginyl residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
  • aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
  • Glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.
  • Cysteinyl residues can be replaced by amino acid residues or other moieties either to eliminate disulfide bonding or, conversely, to stabilize cross- linking. See, e.g., Bhatnagar et al. (1996), T. Med. Chem. 39: 3814-9. Derivatization with bifunctional agents is useful for cross-linking the peptides or their functional derivatives to a water-insoluble support matrix or to other macromolecular vehicles.
  • cross-linking agents include, e.g., l,l-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N- hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'- dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N- maleimido-l,8-octane.
  • Derivatizing agents such as methyl-3-[(p- azidophenyl)dithio]propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light.
  • reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.
  • Carbohydrate (oligosaccharide) groups may conveniently be attached to sites that are known to be glycosylation sites in proteins.
  • O-linked oligosaccharides are attached to serine (Ser) or threonine (Thr) residues while N-linked oligosaccharides are attached to asparagine (Asn) residues when they are part of the sequence Asn-X- Ser/Thr, where X can be any amino acid except proline.
  • X is preferably one of the 19 naturally occurring amino acids other than proline.
  • the structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different.
  • One type of sugar that is commonly found on both is N-acetylneuraminic acid (referred to as sialic acid).
  • Sialic acid is usually the terminal residue of both N-linked and O- linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycosylated compound.
  • site(s) may be incorporated in the linker of the compounds of this invention and are preferably glycosylated by a cell during recombinant production of the polypeptide compounds (e.g., in mammalian cells such as CHO, BHK, COS). However, such sites may further be glycosylated by synthetic or semi-synthetic procedures known in the art.
  • Codons may be substituted to eliminate restriction sites or to include silent restriction sites, which may aid in processing of the DNA in the selected host cell.
  • the vehicle, linker and peptide DNA sequences may be modified to include any of the foregoing sequence changes.
  • Methods of Making The compounds of this invention largely may be made in transformed host cells using recombinant DNA techniques. To do so, a recombinant DNA molecule coding for the peptide is prepared. Methods of preparing such DNA molecules are well known in the art. For instance, sequences coding for the peptides could be excised from DNA using suitable restriction enzymes. Alternatively, the DNA molecule could be synthesized using chemical synthesis techniques, such as the phosphoramidate method. Also, a combination of these techniques could be used.
  • the invention also includes a vector capable of expressing the peptides in an appropriate host.
  • the vector comprises the DNA molecule that codes for the peptides operatively linked to appropriate expression control sequences. Methods of effecting this operative linking, either before or after the DNA molecule is inserted into the vector, are well known.
  • Expression control sequences include promoters, activators, enhancers, operators, ribosomal binding sites, start signals, stop signals, cap signals, polyadenylation signals, and other signals involved with the control of transcription or translation.
  • the resulting vector having the DNA molecule thereon is used to transform an appropriate host. This transformation may be performed using methods well known in the art.
  • Any of a large number of available and well-known host cells may be used in the practice of this invention.
  • the selection of a particular host is dependent upon a number of factors recognized by the art. These include, for example, compatibility with the chosen expression vector, toxicity of the peptides encoded by the DNA molecule, rate of transformation, ease of recovery of the peptides, expression characteristics, bio-safety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for the expression of a particular DNA sequence.
  • useful microbial hosts include bacteria (such as E. coli sp.), yeast (such as Saccharomyces sp.) and other fungi, insects, plants, mammalian (including human) cells in culture, or other hosts known in the art.
  • Host cells may be cultured under conventional fermentation conditions so that the desired compounds are expressed. Such fermentation conditions are well known in the art.
  • the peptides are purified from culture by methods well known in the art.
  • the compounds may also be made by synthetic methods.
  • solid phase synthesis techniques may be used. Suitable techniques are well known in the art, and include those described in Merrifield (1973), Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds.); Merrifield (1963), T. Am. Chem. Soc. 85: 2149; Davis et al. (1985), Biochem. Intl. 10: 394-414; Stewart and Young (1969), Solid Phase Peptide Synthesis: U.S. Pat. No. 3,941,763; Finn et al- (1976), The Proteins (3rd ed.) 2: 105-253; and Erickson et al.
  • Solid phase synthesis is the preferred technique of making individual peptides since it is the most cost-effective method of making small peptides.
  • Compounds that contain derivatized peptides or which contain non-peptide groups may be synthesized by well-known organic chemistry techniques.
  • the compounds of this invention have pharmacologic activity resulting from their interaction with PTH-1 receptor or PTH-2 receptor. Mannstadt et al. (1999), Am. T. Physiol. 277. 5Pt 2. F665-75. PTH and agonists thereof increase bone resorption, increase renal calcium reabsorption, decrease epidermal proliferation, and decrease hair growth. Holick et al. (1994) Proc. Natl. Sci. USA 91 (17): 8014-6; Schilli et aL (1997), T. Invest. Dermatol. 108(6): 928-32. Thus, antagonists of PTH-1 receptor and /or PTH-2 receptor are useful in treating:
  • hypercalcemia including hypercalcemia resulting from solid tumors (breast, lung and kidney) and hematologic malignacies
  • tumor metastases particularly metastases to bone, and particularly related to breast and prostate cancer
  • osteopenia that is related to or aggravated by aberrant PTH receptor signaling, including various forms of osteoporosis, such as:
  • osteoporosis hypothyroidism, hyperparathyroidism, Cushing's syndrome, and acromegaly
  • osteoporosis hereditary and congenital forms of osteoporosis (e.g., osteogenesis imperfecta, homocystinuria, Menkes' syndrome, and Riley-Day syndrome);
  • - osteoporosis secondary to other disorders such as hemochromatosis, hyperprolactinemia, anorexia nervosa, thyrotoxicosis, diabetes mellitus, celiac disease, inflammatory bowel disease, primary biliary cirrhosis, rheumatoid arthritis, ankylosing spondylitis, multiple myeloma, lymphoproliferative diseases, and systemic mastocytosis;
  • - osteoporosis secondary to surgery e.g., gastrectomy
  • drug therapy such as chemotherapy, anticonvulsant therapy, immunosuppressive therapy, and anticoagulant therapy
  • chemotherapy anticonvulsant therapy
  • immunosuppressive therapy immunosuppressive therapy
  • RA rheumatoid arthritis
  • SLE systemic lupus erythematosus
  • asthma temporal arteritis
  • vasculitis chronic obstructive pulmonary disease
  • polymyalgia rheumatica polymyositis
  • chronic interstitial lung disease rheumatoid arthritis
  • SLE systemic lupus erythematosus
  • vasculitis vasculitis
  • chronic obstructive pulmonary disease polymyalgia rheumatica
  • polymyositis chronic interstitial lung disease
  • osteoporosis secondary to glucocorticosteroid and/ or immunomodulatory treatment to prevent organ rejection following organ transplant such as kidney, liver, lung, heart transplants;
  • osteoporosis due to submission to microgravity, such as observed during space travel; - osteoporosis associated with malignant disease, such as breast cancer, prostate cancer;
  • osteomyelitis or an infectious lesion in bone, leading to bone loss
  • osteopenia following surgery, induced by steroid administration, and associated with disorders of the small and large intestine and with chronic hepatic and renal diseases.
  • Osteonecrosis or bone cell death, associated with traumatic injury or nontraumatic necrosis associated with Gaucher's disease, sickle cell anemia, systemic lupus erythematosus, rheumatoid arthritis, periodontal disease, osteolytic metastasis, and other conditions;
  • alopecia deficient hair growth or partial or complete hair loss
  • alopecia male pattern baldness
  • toxic alopecia alopecia senilis
  • alopecia areata
  • alopecia pelada alopecia pelada
  • trichotillomania alopecia pelada
  • PTH receptor agonists are useful as a therapeutic treatment.
  • such indications include fracture repair (including healing of non-union fractures), osteopenia, including various forms of osteoporosis, such as:
  • osteoporosis hypothyroidism, Cushing's syndrome, and acromegaly
  • hereditary and congenital forms of osteoporosis e.g., osteogenesis imperfecta, homocystinuria, Menkes' syndrome, and Riley-Day syndrome
  • osteoporosis due to immobilization of extremities; - osteoporosis secondary to other disorders, such as hemochromatosis, hyperprolactinemia, anorexia nervosa, thyrotoxicosis, diabetes mellitus, celiac disease, inflammatory bowel disease, primary biliary cirrhosis, rheumatoid arthritis, ankylosing spondylitis, multiple myeloma, lymphoproliferative diseases, and systemic mastocytosis;
  • other disorders such as hemochromatosis, hyperprolactinemia, anorexia nervosa, thyrotoxicosis, diabetes mellitus, celiac disease, inflammatory bowel disease, primary biliary cirrhosis, rheumatoid arthritis, ankylosing spondylitis, multiple myeloma, lymphoproliferative diseases, and systemic mastocytosis;
  • osteoporosis secondary to surgery e.g., gastrectomy
  • drug therapy such as chemotherapy, anticonvulsant therapy, immunosuppressive therapy, and anticoagulant therapy
  • osteoporosis secondary to glucocorticosteroid treatment for diseases such as RA, SLE, asthma, temporal arteritis, vasculitis, chronic obstructive pulmonary disease, polymyalgia rheumatica, polymyositis, chronic interstitial lung disease;
  • osteoporosis secondary to glucocorticosteroid and/or immunomodulatory treatment to prevent organ rejection following organ transplant such as kidney, liver, lung, heart transplants;
  • PTH agonists with extended half-life may be used with an inhibitor of bone resorption.
  • Inhibitors of bone resorption include OPG and OPG derivatives, OPG-L (RANKL) antibody, calcitonin (e.g., Miacalcin®, Calcimar®), bisphosphonates (e.g., APD, alendronate, risedronate, eridronate, pamidronate, tiludronate, clodronate, neridronate, ibandronate, zoledronate), estrogens (e.g., Premarin®, Estraderm®, Prempro®, Alora®, Climara®, Vivelle®, Estratab® Ogen®), selective estrogen receptor modulators (e.g., raloxifene, droloxifene, lasofoxifene), tibolone, and the like.
  • Exemplary bone resorption inhibitors are described in W0
  • the compounds of this invention may be appropriate as a monotherapy for the treatment of Osteoporosis, and it is possible that the addition of an antiresorptive agent to PTH-Fc treatment will increase both their efficacy and therapeutic window. Both PTH and PTH-Fc cause an increase in both bone formation and bone resorption. The ability of antiresorptives to block the osteoclast response could limit the hypercalcemic effects of PTH-Fc and could also increase bone mas Pharmaceutical Compositions
  • compositions of the inventive compounds may be for administration for injection, or for oral, pulmonary, nasal, transdermal or other forms of administration.
  • the invention encompasses pharmaceutical compositions comprising effective amounts of a compound of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.
  • Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80,
  • Polysorbate 80 polysorbate 80
  • anti-oxidants e.g., ascorbic acid, sodium metabisulfite
  • preservatives e.g., Thimersol, benzyl alcohol
  • bulking substances e.g., lactose, mannitol
  • incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes.
  • Hyaluronic acid may also be used, and this may have the effect of promoting sustained duration in the circulation.
  • Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Remington's Pharmaceutical Sciences, 18th Ed.
  • compositions may be prepared in liquid form, or may be in dried powder, such as lyophilized form.
  • Implantable sustained release formulations are also contemplated, as are transdermal formulations. Twice weekly dosing of the compounds of this invention is superior to daily injection of PTH (1-34) for increasing osteoblast number, bone volume, and bone mineral density in rodents. In adult mice, twice weekly dosing with PTH-(l-34)-Fc caused greater increases in bone density and bone volume compared to daily PTH-(l-34).
  • the optimal dosing of primates may be less frequent compared to rats or mice. Weekly (or less frequent) dosing may be optimal in primates, based on the observation that the hypercalcemic response of OVX cynomolgus monkeys to a single subcutaneous injection of PTH-(l-34)-Fc (10-34 nmol/kg) persisted for about 168 hours ( Figure 11). This observation suggests that a single subcutaneous dose of PTH-(l-34)-Fc in primates is cleared within about 1 week, which could also represent the maximum dosing frequency required for anabolic effects.
  • Oral dosage forms. Contemplated for use herein are oral solid dosage forms, which are described generally in Chapter 89 of Remington's Pharmaceutical Sciences (1990), 18th Ed., Mack Publishing Co.
  • Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets or pellets.
  • liposomal or proteinoid encapsulation may be used to formulate the present compositions (as, for example, proteinoid microspheres reported in U.S. Patent No. 4,925,673).
  • Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No. 5,013,556).
  • a description of possible solid dosage forms for the therapeutic is given in Chapter 10 of Marshall, K., Modern Pharmaceutics (1979), edited by G. S. Banker and C. T. Rhodes, herein incorporated by reference in its entirety.
  • the formulation will include the inventive compound, and inert ingredients which allow for protection against the stomach environment, and release of the biologically active material in the intestine.
  • the compounds may be chemically modified so that oral delivery is efficacious.
  • the chemical modification contemplated is the attachment of at least one moiety to the compound molecule itself, where said moiety permits (a) inhibition of proteolysis; and (b) uptake into the blood stream from the stomach or intestine.
  • the increase in overall stability of the compound and increase in circulation time in the body are also contemplated.
  • Moieties useful as covalently attached vehicles in this invention may also be used for this purpose. Examples of such moieties include: PEG, copolymers of ethylene glycol and propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone and polyproline.
  • a salt of a modified aliphatic amino acid such as sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
  • SNAC sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
  • the compounds of this invention can be included in the formulation as fine multiparticulates in the form of granules or pellets of particle size about 1 mm.
  • the formulation of the material for capsule administration could also be as a powder, lightly compressed plugs or even as tablets.
  • the therapeutic could be prepared by compression.
  • Colorants and flavoring agents may all be included.
  • the protein (or derivative) may be formulated (such as by liposome or microsphere encapsulation) and then further contained within an edible product, such as a refrigerated beverage containing colorants and flavoring agents.
  • diluents could include carbohydrates, especially mannitol, -lactose, anhydrous lactose, cellulose, sucrose, modified dextrans and starch.
  • Certain inorganic salts may also be used as fillers including calcium triphosphate, magnesium carbonate and sodium chloride.
  • Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.
  • Disintegrants may be included in the formulation of the therapeutic into a solid dosage form. Materials used as disintegrants include but are not limited to starch including the commercial disintegrant based on starch, Explotab.
  • Sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite may all be used.
  • Another form of the disintegrants are the insoluble cationic exchange resins.
  • Powdered gums may be used as disintegrants and as binders and these can include powdered gums such as agar, Karaya or tragacanth. Alginic acid and its sodium salt are also useful as disintegrants.
  • Binders may be used to hold the therapeutic agent together to form a hard tablet and include materials from natural products such as acacia, tragacanth, starch and gelatin. Others include methyl cellulose (MC), ethyl cellulose (EC) and carboxymethyl cellulose (CMC). Polyvinyl pyrrolidone (PVP) and hydroxypropylmethyl cellulose (HPMC) could both be used in alcoholic solutions to granulate the therapeutic.
  • MC methyl cellulose
  • EC ethyl cellulose
  • CMC carboxymethyl cellulose
  • PVP polyvinyl pyrrolidone
  • HPMC hydroxypropylmethyl cellulose
  • Lubricants may be used as a layer between the therapeutic and the die wall, and these can include but are not limited to; stearic acid including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Soluble lubricants may also be used such as sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol of various molecular weights, Carbowax 4000 and 6000.
  • Glidants that might improve the flow properties of the drug during formulation and to aid rearrangement during compression might be added.
  • the glidants may include starch, talc, pyrogenic silica and hydrated silicoaluminate.
  • a surfactant might be added as a wetting agent.
  • Surfactants may include anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate.
  • Cationic detergents might be used and could include benzalkonium chloride or benzethonium chloride.
  • nonionic detergents that could be included in the formulation as surfactants are lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. These surfactants could be present in the formulation of the protein or derivative either alone or as a mixture in different ratios.
  • Additives may also be included in the formulation to enhance uptake of the compound. Additives potentially having this property are for instance the fatty acids oleic acid, linoleic acid and linolenic acid.
  • Controlled release formulation may be desirable.
  • the compound of this invention could be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms e.g., gums.
  • Slowly degenerating matrices may also be incorporated into the formulation, e.g., alginates, polysaccharides.
  • Another form of a controlled release of the compounds of this invention is by a method based on the Oros therapeutic system (Alza Corp.), i.e., the drug is enclosed in a semipermeable membrane which allows water to enter and push drug out through a single small opening due to osmotic effects. Some enteric coatings also have a delayed release effect.
  • coatings may be used for the formulation. These include a variety of sugars which could be applied in a coating pan.
  • the therapeutic agent could also be given in a film coated tablet and the materials used in this instance are divided into 2 groups.
  • the first are the nonenteric materials and include methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols.
  • the second group consists of the enteric materials that are commonly esters of phthalic acid.
  • Film coating may be carried out in a pan coater or in a fluidized bed or by compression coating.
  • Pulmonary delivery forms are also contemplated herein.
  • the protein (or derivative) is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream.
  • Adjei et al. Pharma. Res. (1990) 7: 565-9
  • Adjei et al. (1990), Internatl. T. Pharmaceutics 63: 135-44 (leuprolide acetate); Braquet et al. (1989), T. Cardiovasc. Pharmacol. 13 (suppl.5): s.143-146 (endothelin- 1); Hubbard et al. (1989), Annals Int.
  • Contemplated for use in the practice of this invention are a wide range of mechanical devices designed for pulmonary delivery of therapeutic products, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
  • Some specific examples of commercially available devices suitable for the practice of this invention are the Ultravent nebulizer, manufactured by Mallinckrodt, Inc., St. Louis, Missouri; the Acorn II nebulizer, manufactured by Marquest Medical Products, Englewood, Colorado; the Ventolin metered dose inhaler, manufactured by Glaxo Inc., Research Triangle Park, North Carolina; and the Spinhaler powder inhaler, manufactured by Fisons Corp., Bedford, Massachusetts.
  • each formulation is specific to the type of device employed and may involve the use of an appropriate propellant material, in addition to diluents, adjuvants and /or carriers useful in therapy.
  • the inventive compound should most advantageously be prepared in particulate form with an average particle size of less than 10 ⁇ m (or microns), most preferably 0.5 to 5 ⁇ m, for most effective delivery to the distal lung.
  • Pharmaceutically acceptable carriers include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol.
  • Other ingredients for use in formulations may include DPPC, DOPE, DSPC and DOPC.
  • Natural or synthetic surfactants may be used.
  • PEG may be used (even apart from its use in derivatizing the protein or analog).
  • Dextrans such as cyclodextran, may be used.
  • Bile salts and other related enhancers may be used.
  • Cellulose and cellulose derivatives may be used.
  • Amino acids may be used, such as use in a buffer formulation.
  • Formulations suitable for use with a nebulizer will typically comprise the inventive compound dissolved in water at a concentration of about 0.1 to 25 mg of biologically active protein per mL of solution.
  • the formulation may also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure).
  • the nebulizer formulation may also contain a surfactant, to reduce or prevent surface induced aggregation of the protein caused by atomization of the solution in forming the aerosol.
  • Formulations for use with a metered-dose inhaler device will generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant.
  • the propellant may be any conventional material employed for this purpose, such as a chlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or a hydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2- tetrafluoroethane, or combinations thereof.
  • Suitable surfactants include sorbitan trioleate and soya lecithin. Oleic acid may also be useful as a surfactant.
  • Formulations for dispensing from a powder inhaler device will comprise a finely divided dry powder containing the inventive compound and may also include a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
  • a bulking agent such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in amounts which facilitate dispersal of the powder from the device, e.g., 50 to 90% by weight of the formulation.
  • Nasal delivery forms Nasal delivery of the inventive compound is also contemplated. Nasal delivery allows the passage of the protein to the blood stream directly after administering the therapeutic product to the nose, without the necessity for deposition of the product in the lung.
  • Formulations for nasal delivery include those with dextran or cyclodextran. Delivery via transport across other mucous membranes is also contemplated. Dosages. The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician, considering various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, the daily regimen should be in the range of 0.1-1000 micrograms of the inventive compound per kilogram of body weight, preferably 0.1-150 micrograms per kilogram.
  • the inventors have determined preferred structures for the preferred peptides listed in Table 4 below.
  • the symbol " ⁇ " may be any of the linkers described herein or may simply represent a normal peptide bond (i.e., so that no linker is present). Tandem repeats and linkers are shown separated by dashes for clarity.
  • F is an Fc domain as defined previously herein or PEG
  • PEG is a molecule comprising polyethylene glycol as described previously herein (e.g., mPEG, which is preferred), which may comprise any linker to enable attachment of polyethylene glycol known in the art.
  • the inventors further contemplate heterodimers in which each strand of an Fc dimer is linked to a different peptide sequence; for example, a molecule in which one strand can be described by SEQ ID NO: 166, the other by SEQ ID NO: 170 or an Fc linked with any of the sequences in Tables 1A, IB, and 2. All of the compounds of this invention can be prepared by methods described in (WO 00/24782).
  • Parathyroid hormone [PTH-(l-34) or native PTH-(l-84)] causes increased bone formation and increased bone mass when injected daily. This anabolic response was previously thought to require brief exposure to PTH, which is facilitated by the short half-life (less than 1 h) of PTH. Clinically, the anabolic effect of PTH therapy requires daily SC injection, which is a significant barrier to the widespread use of PTH. Less frequent injections of PTH would be clinically desirable and could be achieved by increasing the in vivo half-life of PTH.
  • Co-administration of a potent bone resorption inhibitor may provide greater effect.
  • This regimen would theoretically permit the unopposed stimulation of bone formation by PTH, leading to increased bone mass.
  • other bone resorption inhibitors including bisphosphonates or estrogen, would also inhibit PTH-induced bone resorption and could therefore be used in combination with a long- acting PTH molecule.
  • PTH-(l-34)-Fc Fc conjugation of proteins causes a significant increase in their circulating half life, which may permit injections of PTH-(l-34)-Fc on a schedule similar to or identical to that of OPG-Fc.
  • the benefits of this invention include less frequent injections of PTH, from the current standard of once per day to as infrequently as once per quarter.
  • Group 1 Vehicle controls (PBS, injected SC, Days 1, 3, and 5)
  • Group 2 OPG-Fc, single SC injection (1 mg/kg) on Day 1
  • Group 3 PTH-(l-34), SC injections on Days 1, 3, and 5, at 20 nMoles PTH/kg/injection. This represents an optimal anabolic PTH regimen.
  • Group 4 Same as group 3, but with a single OPG-Fc injection on Day l.
  • Group 5 Single SC injection of PTH-(l-34)-Fc at 60 nMoles/kg, on
  • Group 6 Same as group 5, but with a single OPG-Fc injection (SC, 1 mg/kg) on Day 1. DEXA of the lumbar spine was performed again on Day 7 to evaluate changes in BMD.
  • BMD in L3 increased modestly with a single injection of OPG-Fc, or with 3 injections of PTH-(l-34), compared to PBS- treated rats ( Figure 5).
  • PTH-(l-34) + OPG caused a greater increase in BMD than either OPG or PTH-(l-34) alone.
  • a single injection of PTH-(l-34)-Fc failed to increase BMD.
  • Figure 5 shows the effect of PTH-Fc + OPG-Fc on bone mineral density (BMD) in the third lumbar vertebra (L3).
  • BMD bone mineral density
  • PTH or PTHrP Several disease states are associated with increased circulating levels of PTH or PTHrP.
  • Primary and secondary hyperparathyroidism PHPT and SHPT, respectively
  • HMM humoral hypercalcemia of malignancy
  • Both proteins signal through the common PTH/PTHrP receptor (PTH-R1) to cause increases in bone resorption, renal calcium reabsorption, and renal biosynthesis of vitamin D.
  • PTH-R1 PTH/PTHrP receptor
  • bone resorption inhibitors have variable success in inhibiting osteoclastic bone resorption in these disease states, no therapy currently mitigates the intestinal and renal influence of PTH or PTHrP excess on calcemia.
  • Agents which directly antagonize PTH or PTHrP signaling are therefore likely to have greater efficacy compared to resorption inhibitors.
  • PTH-(7-34) peptides are fairly effective PTH- Rl antagonists with very mild agonist activity. Compared to PTH-(7-34), PTHrP-(7-34) peptide has greater affinity for PTH-Rl and as such is a more potent antagonist. However, PTHrP-(7-34) also has greater (but still mild) agonist activity compared to PTH-(7-34) (McKee (1990), Endocrinol. 127: 76). The optimal antagonist may combine the weaker agonism of PTH-(7-34) with the stronger antagonism of PTHrP-(7-34).
  • BIC blood ionized calcium
  • [AsnlO,Leull]PTHrP-(7- 34)-Fc at 10 mg/kg caused a more rapid normalization of PTHrP-induced hypercalcemia compared to vehicle treatment.
  • a dose of 30 mg/kg completely blocked the calcemic response to PTHrP-(l-34) ( Figure 6).
  • PTH-(l-34)-Fc was used as a long- acting calcemic agent. This study also represents a model for primary and secondary hyperparathyroidism, diseases which are characterized by persistent elevation of PTH levels.
  • mice Four week old male mice were injected on days 0, 5, and 10 with vehicle or with PTH fragments, by SC injection. Peripheral blood was obtained for clinical chemistry at 24, 48, and 72 h. Mice were killed on day 15, vertebrae, tibiae and femurs were harvested for histology and one tibia was collected for bone density measurements (peripheral quantitative computed tomography, pQCT).
  • Clinical chemistry endpoints included total serum calcium, serum alkaline phosphatase (AP, a marker of osteoblast activity), and serum tartrate- resistant acid phosphatase (TRAP, a marker of osteoclast activity). For each animal, the ratio of AP:TRAP was calculated as an index of relative osteoblast activity compared to osteoclast activity. A higher AP:TRAP ratio would indicate a potentially more anabolic agent.
  • the relatively high doses (15-fold greater than optimal anabolic doses) were selected base on previous studies which demonstrated significant changes in clinical chemistry endpoints. It was anticipated that lower doses might be required to demonstrate anabolic effects on bone density, and that antiresorptive co-treatment might also be required to achieve anabolic responses.
  • Serum AP (osteoblast marker) was unchanged by PTH-(l-34) administration, but was significantly elevated by 300 nmoles/kg of PTH- (l-34)-Fc and by PTH-(1-31)-Fc at 72 h.
  • PTH-(l-30)-Fc demonstrated the greatest elevation of AP, which peaked 72 h after injection of 1,000 nmoles/kg ( Figure 8B).
  • Serum TRAP osteoclast marker
  • the calculated AP:TRAP ratios were unchanged by PTH-(l-34), and were increased over time by PTH-(l-34)-Fc.
  • the low dose of PTH-(1-31)-Fc (100 nmoles/kg) increased AP:TRAP, while the high dose (1,000 nmoles/kg) decreased AP:TRAP.
  • the greatest increase in AP:TRAP was realized with PTH-(1- 30)-Fc (1,000 nmoles/kg) (Figure 8D).
  • PTH-(l-30)-Fc caused the greatest increase in bone density.
  • the reverse dose- response was consistent with the notion that doses employed (chosen for clinical chemistry endpoints) were 5-50 fold higher than the optimal anabolic doses.
  • Low doses of PTH (or PTH-Fc) which fail to significantly increase serum calcium are optimal for anabolic effects. See Hock, J.M. (1992), T. Bone Min. Res. 7:65-72.
  • the treatment regimen with the greatest anabolic effect was also the only PTH-Fc treatment which failed to significantly increase serum calcium (Figure 8A).
  • mice Male BDFl mice (4 months of age) were treated twice per week by subcutaneous injection with various doses of PTH-(1- 34)-Fc or with vehicle (PBS). Other mice were treated daily with SC injections of PTH-(l-34) at a dose of 80 ⁇ g/kg/day (20 nmol/kg/ day), a treatment regimen which is optimal for increasing bone mass in rodents (M. Gunness-Hey and J.M. Hock, Metab. Bone Pis. & Rel. Res. 5:177-181, 1984).
  • mice were sacrificed and tibiae were analyzed for bone mineral density (BMD) via pQCT (Figure 10).
  • Total tibial BMD and cancelled BMD were both significantly increased by daily PTH-(l-34) injections compared to vehicle-treated controls ( Figure 1, two-way ANOVA, p ⁇ 0.05).
  • Twice-weekly injections of PTH-(l-34)-Fc caused dose-dependent increases in both total and cancellous BMD which, at the two highest doses (50 and 150 nmol/kg), were significantly greater than the effects of either vehicle or daily PTH-(1- 34).
  • Cortical BMD in the tibia was not significantly enhanced by daily PTH-(l-34) treatments.
  • Twice-weekly PTH-(l-34)-Fc caused a dose- dependent increase in cortical BMD which at the highest dose was signficantly greater than that observed in mice treated with vehicle or with daily PTH-(l-34) (p ⁇ 0.05).
  • Twice-weekly PTH-(l-34)-Fc also effectively increased BMD as a monotherapy in aged ovariectomized (OVX) rats.
  • OVX ovariectomized rats
  • Sprague Dawley rats were OVX'd at 3 months of age and allowed to lose bone for 11 months.
  • Other rats were sham-operated and treated twice per week with vehicle (PBS).
  • OVX rats were treated twice per week with SC injections of either vehicle or the bisphosphonate APD (pamidronate, 0.5 mg/kg), or with PTH-(l-34)-Fc (50 nmol/kg) or with APD + PTH-(l-34)-Fc.
  • BMD was determined weekly via dual energy X-ray absorptiometry (DEXA).
  • Rats were sacrificed after 4 weeks of treatment.
  • OVX rats had significant reductions in BMD at all skeletal sites analyzed, compared to vehicle-treated OVX rats ( Figure 11, p ⁇ 0.05, 2-way ANOVA).
  • APD alone did not significantly increase BMD at any skeletal site compared to vehicle-treated OVX rats.
  • PTH-(l-34)-Fc alone caused a significant increase in BMD at the femoral metaphysis after 4 weeks of treatment (p ⁇ 0.05).
  • Treatment of OVX rats with PTH + ABD was associated with an earlier significant increase in BMD at this site (3 weeks).
  • PTH-(l-34)-Fc is an effective anabolic agent when used as a monotherapy in both adult mice and aged OVX rats.
  • APD antiresorptive agent
  • Co-administration of APD also blocked the transient hypercalcemic response produced by PTH-(l-34)-Fc, which suggests that the therapeutic index of PTH-(l-34)-Fc could be significantly improved by co-administering an effective antiresorptive agent.
  • Example 5 PEG PTH ANALOGUES Cys mutations were introduced into PTH(l-34) to provide PEGylation sites. The initial cysteine positions were selected based on structure /function activity data suggesting that the C-terminal domain may be most tolerant to PEGylation. These analogs represent a substitution mutant K27C, an insertion mutant at C33 and the dual mutant combining both cysteine positions:
  • PTH (1-34) analog (Cys 27) (SEQ ID NO: 188, appearing in Table IB): PTH (1-34) analog (Cys 33) (SEQ ID NO: 174, appearing in Table IB): PTH (1-34) analog (Cys 27/33) (SEQ ID NO: 172, appearing in Table IB): Additional cysteine analogs of PTH (1-34) have also been prepared
  • TFA was purchased from either PE Applied Biosystems (Foster City, CA) or Chem-Impex (Wood Dale, IL). All reagents for amino acid analysis were purchased from PE Applied Biosystems (Foster City, CA). All chemicals were of the highest grade possible.
  • Solid-phase peptide synthesis of PTHfl-34) and analogues All peptides were prepared by solid phase synthesis using the Fmoc/t-butyl- based methodology with Fmoc-Phe-Wang or Fmoc-Cyc(Trt)-Wang resin as a solid support.
  • the sidechain protection scheme is as follows: Arg(Pbf), Asn(Trt), Asp(OtBu), Cys(Trt), Gln(Trt), Glu(OtBu), His(Trt), Lys(Boc), Ser(tBu), and Trp(Boc).
  • Each coupling consisted of the following modules: (i) removal of the ⁇ -amino Fmoc protection by piperidine in NMP (ABI instrument) or NEM in DMF (Rainin instrument); (ii) activation with either HBTU or DCC followed by (iii) single 60-minute coupling of the HOBt ester of the Fmoc amino acid (20, 10, or 5 equivalents) in NMP or DMF; (iv) resin washes.
  • the peptide-resin was dried in vacuo and subjected to acidolytic deprotection and cleavage (TFA:H 2 0:TIS:EDT:thioanisol (85:5:5:2.5:2.5, 10 ml, 4 hr, 20 °C).
  • acidolytic deprotection and cleavage (TFA:H 2 0:TIS:EDT:thioanisol (85:5:5:2.5:2.5, 10 ml, 4 hr, 20 °C).
  • the resin/peptide suspension was filtered, peptide-filtrate was precipitated using cold diethyl ether (40 ml), pelleted by centrifugation, washed with cold diethyl ether (2x , 40 ml), and dried in vacuo or by speedvac.
  • the precipitated crude peptides were analyzed by HPLC-MS for crude purity and expected molecular ion.
  • Analytical HPLC was carried out on a Vydac (Hesperia, CA) 214TPTM C18 column (300 A pore size, 5 ⁇ m particle size, 0.46 x 25 cm).
  • the conditions for this and all subsequent primary analytical RP-HPLC were linear gradients of 5-50% ACN in 0.1% aqueous TFA over 25 minutes, and a flow rate of 1.0 ml/min, unless otherwise noted.
  • the effluent was monitored with a PDA detector from which the 220 nm absorbance profile was extracted. Electrospray Mass Spectrometry.
  • Mass spectra of all peptides were obtained with an PE-Sciex API-I (Thornhill, ON) single quadrupole electrospray mass spectrometer equipped with a nebulizer-assisted electrospray source.
  • Samples of preparative HPLC fractions were introduced by means of an Alltech (Deerfield, IL) 426 HPLC pump and Perkin Elmer (Norwalk, CT) Series 200 autosampler, using a 0.40 ml/min isocratic gradient of 1 mM NH 4 OAc in ACN:H 2 0 (50:50).
  • the mass spectrometer was scanned from mass to charge (m/z) 300 to 2400 for the characterization of the purified peptide.
  • the conditions for this chromatography were a linear gradient of 5 to 50% ACN in 0.1% aqueous TFA over 45 minutes, and a flow rate of 0.4 ml/min. Samples were also analyzed on a Vydac (Hesperia, CA) 218TPTM C18 column (300 A pore size, 5 ⁇ m particle size, 0.46 x 25 cm). The conditions for this analysis were a linear gradient of 5 to 20% ACN in 0.1% aqueous TFA over 10 minutes, followed by 20 to 50% ACN in 0.1% aqueous TFA over 40 minutes, and a flow rate of 1 ml/min. All secondary analytical RP-HPLC were monitored with a PDA detector from which the 220 nm absorbance result was extracted.
  • the amino acid mixture was then separated by RP-HPLC on a Brownlee PTC C18 column (2.1 x 220 mm) with a linear gradient of 2% to 11% ACN in H 2 0 over 4 minutes, 11% to 27% ACN in H 2 0 over 6 minutes, and 27% to 47% ACN in H 2 0 over 10 minutes. Both solvents were buffered with NaOAc to pH 5.4, and the flow rate was 0.3 ml/min. Quantitative amino acid analyses were performed in triplicate, and composition was determined by comparison of each amino acid peak area in the peptide to the area of a known amount of amino acid standard.
  • PEGylation The PTH (1-34) cysteine analogs were PEGylated with a variety of PEG-maleimides, as shown in Reaction Scheme 1 below.
  • the PEGylation reactions were carried out in 20 mM sodium phosphate, 5 mM EDTA, pH 6.5 with PTH (1-34) peptide concentrations from 2-10 mg/ml and PEG:peptide stoichiometry of 0.5 to 5 fold molar excess. Although reactant concentrations may exceed these limits, the preferred conditions are 5 mg/ml peptide with an equimolar PEG- maleimide concentration. Reaction times may range from 15 minutes to overnight at room temperature or 4 degrees C, with 2 hours at room temperature preferred. Optionally, the reaction may be stopped with the addition of excess mercaptan, such as ⁇ -mercaptoethanol.
  • excess mercaptan such as ⁇ -mercaptoethanol.
  • PTH (1-34) PEGylation can be achieved by coupling in non-aqueous solvents or through orthogonal approaches during peptide synthesis.
  • the PEG-PTH (1-34) conjugates were then purified by aqueous phase cation exchange chromatography ( Figure 13).
  • PEG-PTH molecules were screened in vitro for evidence of PTH receptor (PTHRl) activation by monitoring production of cAMP in murine MC3T3-E1 osteoblast cultures.
  • PTH-(l-34) peptide consistently demonstrates the greatest potency in this assay, while PTH-(l-34)-Fc is a full agonist with slightly reduced potency.
  • the mutant peptide analogs used for PEGylation (C27, C33 and C27/33) had potencies in the cAMP assay that were similar to each other and to PTH-(l-34)-Fc ( Figure 14A through 14D). In most cases, PEGylation of these peptides had little effect on their relative potency in cAMP assays, and all PEG contructs appeared to behave as full agonists.
  • the longer duration of hypercalcemia with PTH-Fc reflects a longer circulating half-life, an attribute which also permits less frequent dosing relative to PTH peptide.
  • no hypercalcemic responses were evident at 24 hours after injection of the non-PEGylated peptides PTH-(l-34), C27, or C33. This observation is consistent with the predicted short half-life of these peptides.
  • PEG-PTH constructs caused hypercalcemic responses which were similar to those observed with equimolar doses of PTH-(l-34)-Fc, including: • C27-20K
  • Trt trityl (triphenylmethyl)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP02793926A 2002-11-01 2002-11-01 Modulatoren von rezeptoren für nebenschilddrüsenhormon- und nebenschildsrüsenhormonbezogene proteine Withdrawn EP1567178A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/036419 WO2004060386A1 (en) 2002-11-01 2002-11-01 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein

Publications (2)

Publication Number Publication Date
EP1567178A1 true EP1567178A1 (de) 2005-08-31
EP1567178A4 EP1567178A4 (de) 2009-07-15

Family

ID=32710245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02793926A Withdrawn EP1567178A4 (de) 2002-11-01 2002-11-01 Modulatoren von rezeptoren für nebenschilddrüsenhormon- und nebenschildsrüsenhormonbezogene proteine

Country Status (4)

Country Link
EP (1) EP1567178A4 (de)
AU (1) AU2002359391A1 (de)
CA (1) CA2511966A1 (de)
WO (1) WO2004060386A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059291A2 (en) 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PE20070684A1 (es) * 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP2573111A1 (de) 2006-04-20 2013-03-27 Amgen Inc. GLP-1-Verbindungen
CA2664734C (en) 2006-10-03 2023-08-01 Radius Health, Inc. Method of drug delivery for bone anabolic protein
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
AU2007313001B2 (en) 2006-10-13 2012-03-22 Eli Lilly And Company Pegylated PTH as PTH receptor modulators and uses thereof
EP2509996A1 (de) 2009-12-07 2012-10-17 Michigan Technological University Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons
KR20150122786A (ko) 2013-03-15 2015-11-02 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 암 전이의 진단, 예후 및 치료를 위한 방법
CN113750091A (zh) 2015-04-29 2021-12-07 雷迪厄斯制药公司 用于治疗癌症的方法
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR20210030393A (ko) 2018-07-04 2021-03-17 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006846A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
WO1998005683A1 (en) * 1996-08-02 1998-02-12 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001081415A2 (en) * 2000-04-27 2001-11-01 Amgen Inc. Parathyroid hormone and parathyroid hormone-related protein antagonists
WO2002068459A2 (en) * 2001-02-21 2002-09-06 Clontech Laboratories, Inc. Non aggregating fluorescent proteins and methods for using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
DE69942035D1 (de) * 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006846A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
WO1998005683A1 (en) * 1996-08-02 1998-02-12 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001081415A2 (en) * 2000-04-27 2001-11-01 Amgen Inc. Parathyroid hormone and parathyroid hormone-related protein antagonists
WO2002068459A2 (en) * 2001-02-21 2002-09-06 Clontech Laboratories, Inc. Non aggregating fluorescent proteins and methods for using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARBIER JEAN-RENE ET AL: "Structure and activities of constrained analogues of human parathyroid hormone and parathyroid hormone-related peptide: Implications for receptor-activating conformations of the hormones" BIOCHEMISTRY, vol. 39, no. 47, 28 November 2000 (2000-11-28), pages 14522-14530, XP002530193 ISSN: 0006-2960 *
KINSTLER O ET AL: "Mono-N-terminal poly(ethylene glycol)-protein conjugates" ADVANCED DRUG DELIVERY REVIEWS 20020617 NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 477-485, XP002530194 ISSN: 0169-409X *
See also references of WO2004060386A1 *

Also Published As

Publication number Publication date
AU2002359391A1 (en) 2004-07-29
EP1567178A4 (de) 2009-07-15
CA2511966A1 (en) 2004-07-22
WO2004060386A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2001257321B2 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
AU2001257321A1 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
US20050124537A1 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6677136B2 (en) Glucagon antagonists
EP1290013B1 (de) Peptidderivate des apolipoproteins-a1/aii
WO2004060386A1 (en) Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
AU2001257173A1 (en) Apo-AI/AII peptide derivatives
JP2007091747A (ja) 治療薬としての修飾ペプチド
EP1800691A2 (de) Verfahren und Zusammensetzungen zur Prevention oder Behandlung von Krebs und von Krebs assoziertem Knochenverlust
US20020090646A1 (en) Calcitonin-related molecules
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
AU2005237128A1 (en) Compositions and Methods for the Prevention or Treatment of Cancer and Bone Loss Associated with Cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KINSTLER, OLAF, BORIS

Inventor name: JAROSINSKI, MARK, ANTHONY

Inventor name: GEGG, COLIN, V.

Inventor name: KOSTENUIK, PAUL

A4 Supplementary search report drawn up and despatched

Effective date: 20090615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090915